Trials / Completed
CompletedNCT05941793
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants With Mild to Moderate COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Oneness Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MBS-COV | MBS-COV for inhalation |
| DRUG | Placebo | Placebo for inhalation |
Timeline
- Start date
- 2023-09-11
- Primary completion
- 2024-08-12
- Completion
- 2024-08-12
- First posted
- 2023-07-12
- Last updated
- 2024-09-19
Locations
5 sites across 2 countries: United States, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05941793. Inclusion in this directory is not an endorsement.